
Glaukos (GKOS) Stock Forecast & Price Target
Glaukos (GKOS) Analyst Ratings
Bulls say
Glaukos Corp has demonstrated robust growth potential, particularly in its Corneal Health segment, which is projected to expand by 9.4% in FY26, with increased momentum anticipated in the latter half of the fiscal year as reimbursement for Epioxa improves. The company's innovative iDose TR product has begun to see higher sales traction, with an impressive gross margin of 85.1% in 4Q25, surpassing market expectations and contributing to an increase in revenue estimates for FY26. Additionally, the strong performance of Glaukos's iStent platform, with an estimated growth of approximately 7% year-over-year, further solidifies the positive financial outlook for the company.
Bears say
Glaukos Corp demonstrated a mixed financial performance, with domestic glaucoma revenue of $86 million exceeding consensus estimates, but overall growth metrics showed signs of decline, with slower growth rates for both domestic and international revenues compared to previous quarters. The company faces challenges with its micro-invasive glaucoma surgery (MIGS) segment and anticipates lowering legacy glaucoma sales growth forecasts due to increasing market headwinds and competition, which may impact future revenue generation. Adjusted earnings per share (EPS) estimates for 2026 and 2027 have been significantly revised downward, indicating a more pessimistic outlook for profitability amid concerns regarding market dynamics and product adoption rates.
This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.
Glaukos (GKOS) Analyst Forecast & Price Prediction
Start investing in Glaukos (GKOS)
Order type
Buy in
Order amount
Est. shares
0 shares